The U.S. Food and Drug Administration (FDA) has approved Khindivi (hydrocortisone) oral solution as a replacement therapy in patients five years of age and older with adrenocortical insufficiency.
Adrenocortical insufficiency is an endocrine disorder characterized by the underproduction of cortisol by the adrenal glands. Primary adrenal insufficiency is a rare form of the condition that occurs when the adrenal glands are damaged. Cortisol is necessary for the body to break down fats, proteins, and carbohydrates, as well as controlling blood pressure and immune system function. Common symptoms of the disease include weakness, fatigue, dizziness, dark skin, weight loss, dehydration and lack of appetite, and muscle aches, among others.
Khindivi is a corticosteroid and the only oral solution formula of hydrocortisone. As a ready-to-use oral liquid solution, the treatment allows simplicity and dosing accuracy in administration. It also opens up access to treatment for patients who have difficulty swallowing pills or who have special administration needs.
For more information, click here.
To learn more about rare endocrine conditions, visit https://checkrare.com/diseases/endocrine-disorders/
